- In May 2024, Genialis introduced a machine learning-based biomarker tool called Genialis krasID, designed to help identify patients most likely to benefit from KRAS inhibitors. This innovative tool also offers an in-depth analysis of response rates and the extent of effectiveness, helping personalize cancer treatment strategies and improve patient outcomes
- In April 2024, Owlstone Medical received a significant grant of USD 1.5 million from the Bill & Melinda Gates Foundation. The funding aims to advance their development of breath-based diagnostics, focusing on the identification of breath biomarkers for diseases such as tuberculosis and human immunodeficiency virus (HIV). This project holds the potential to revolutionize diagnostic approaches for these infectious diseases by providing non-invasive, rapid, and highly accurate testing methods
- In April 2024, Bio-Rad Laboratories launched the ddPLEX ESR1 mutation detection kit, an ultrasensitive and multiplexed digital PCR assay. This kit is designed to detect ESR1 mutations in breast cancer during clinical research, enabling more precise detection and monitoring of treatment efficacy. The advancement of this kit could contribute to more effective management of breast cancer by helping clinicians track mutations that influence treatment decisions
- In March 2024, Koneksa, a company focused on developing evidence-based biomarkers, announced a partnership with Merck through its Data Syndication Partnership Program. The collaboration aims to accelerate the development of digital biomarkers for neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. This initiative is expected to help create innovative tools for early detection, monitoring disease progression, and optimizing treatment strategies, ultimately improving patient care in neurodegenerative diseases
